Land: Irland
Sprog: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
CANINE DISTEMPER VIRUS, LIVE, CANINE ADENOVIRUS TYPE 2, LIVE, CANINE PARVOVIRUS, LIVE, CANINE PARAINFLUENZA VIRUS, LIVE
Merial Animal Health Limited
QI07AD04
CANINE DISTEMPER VIRUS, LIVE, CANINE ADENOVIRUS TYPE 2, LIVE, CANINE PARVOVIRUS, LIVE, CANINE PARAINFLUENZA VIRUS, LIVE
Unknown
Lyophilisate and solvent for solution for injection
POM
Canine
Canine distemper virus vaccine + Canine adenovirus vaccine + Canine parvovirus vaccine + Canine para
Immunological - Live Vaccine
Authorised
2016-07-22
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DAPPi lyophilisate and solvent for suspension for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of lyophilisate contains: ACTIVE SUBSTANCES: MINIMUM MAXIMUM Attenuated Canine Distemper virus, strain BA5 10 4.0 CCID 50 * 10 6.0 CCID 50 * Attenuated Canine Adenovirus type 2, strain DK13 10 2.5 CCID 50 * 10 6.3 CCID 50 * Attenuated Canine Parvovirus type 2, strain CAG2 10 4.9 CCID 50 * 10 7.1 CCID 50 * Attenuated Canine Parainfluenza virus type 2, strain 10 4.7 CCID 50 * 10 7.1 CCID 50 * CGF 2004/75 (* CCID 50 : 50 % cell culture infective dose) SOLVENT: Sterile water 1 ml EXCIPIENTS: For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection Beige to pale yellow lyophilisate and colourless solution for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 22/07/2016_ _CRN 7022449_ _page number: 1_ 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of dogs to: - prevent mortality and clinical signs caused by canine distemper virus (CDV), - prevent mortality and clinical signs caused by infectious canine hepatitis virus (CAV), - reduce viral excretion during respiratory disease caused by canine adenovirus type 2 (CAV-2), - prevent mortality, clinical signs and viral excretion caused by canine parvovirus (CPV)*, - reduce viral excretion caused by canine parainfluenza virus type 2 (CPiV), Onset of immunity: 2 weeks for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains. Current available challenge Læs hele dokumentet